Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543400 · ClinicalTrials.gov registry record · Phase 2
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
A Phase 2 study, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 503
- Enrollment target
NCT00543400: Completed Phase 2 study, sponsored by Momenta Pharmaceuticals.
NCT00543400 is a Phase 2 study that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 503 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (278% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543400, a Phase 2 study, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 503 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The secondary objectives are to evaluate the effect of M118 on procedural indices including procedure success, abrupt closure, post-procedure TIMI flow, and catheter thrombus. Substudy Primary Objective The primary objective of the substudy is to characterize the pharmacokinetic and pharmacodynamic profile of M118 among subjects with stable coronary artery disease undergoing elective PCI.
Interventions
- DRUG Unfractionated Heparin
- DRUG M118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00543400 record still lists
NCT00543400 is an interventional study that assigns participants to a tested intervention. The registered 503 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (278% higher).
The record links to 0 conditions, and to 2 interventions - of which Unfractionated Heparin is the first listed.
NCT00543400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00543400 about?
NCT00543400 is a clinical study titled "Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)". The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The secondary objectives are to evaluate the effect of M118 on proced...
What is the current status of trial NCT00543400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 503 participants. The study started on 2007-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00543400?
The interventions under investigation include: Unfractionated Heparin (DRUG), M118 (DRUG).
Who is sponsoring clinical trial NCT00543400?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00543400's enrollment target sits among peer trials
503 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- NCT06736522 · 504 participants · NA
Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia